$HGTY

Hagerty (HGTY) Q3 2025 Earnings Call Transcript

Image source: The Motley Fool.Tuesday, Nov. 4, 2025 at 10 a.m. ETChief Executive Officer and Chairman - McKeel HagertyContinue reading ...

Original reporting
Motley Fool · https://www.facebook.com/themotleyfool/, Motley Fool Transcribing
Published Nov 4, 2025, 4:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 4, 2025, 5:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Hagerty (HGTY) Q3 2025 Earnings Call Transcript — source image
Decision brief

The 30-second read

$HGTYBullishMed
01

Why it matters

Positive earnings may lead to short-term stock appreciation; however, broader market conditions could influence actual price movements.

02

Market read

The earnings call is highly relevant for traders focusing on the financial and insurance sectors, with potential ripple effects across related industries.

03

What to watch

Potential impact of upcoming regulatory changes or macroeconomic data releases that could offset earnings positives.

Timing: High; earnings call provides timely information for trading decisions within the next few days.

Background

Hagerty's Q3 2025 earnings call highlights strong financial performance amid a competitive insurance market.

Company-level read

Ticker impact

$HGTYBullishMedium confidence
Context

Primary focus of the earnings call transcript, indicating high relevance for trading decisions.

Expected impact

Moderate upward movement expected in the short term; potential for increased volatility around earnings release.

Evidence & confidence

The earnings call indicates favorable financial performance, but market reaction may vary due to broader economic factors.

Market effects

Positive outlook for the insurance and financial sectors, potentially boosting sector ETFs.

Limited regional impact; primarily affecting US markets.

Moderate; US financial sector performance can influence global financial indices.

Counterpoint

Earnings optimism may be already priced in; unexpected macroeconomic developments could lead to a reversal.

Key entities

  • Hagerty Inc.

    Insurance company specializing in classic car insurance and related services.

  • McKeel Hagerty

    CEO and Chairman of Hagerty Inc.

Related articles

$HGTYMedAI 9/10

Hagerty Reports Second Quarter 2026 Results

Hagerty, Inc. (NYSE: HGTY) reported second quarter and first-half 2026 results, citing record member and premium growth and an increased 2026 outlook. First-half written premium rose 19% to $713 million and earned premium rose 42% to $492 million. Net loss was $5 million, including $153 million of Markel Fronting transitional costs. Adjusted EBITDA rose 32% to $160 million; 2026 guidance: written premium growth 16% to 17%, net income $18 to $30 million, and adjusted EBITDA $270 to $280 million.

$HGTYHigh

Hagerty, Inc. (HGTY): Results of Operations and Financial Condition

Hagerty, Inc. (HGTY) filed an SEC Form 8-K — Results of Operations and Financial Condition. STOCKHOLDER LETTER Q2 2026 Every summer, Hagerty Drivers Club magazine names its Road of the Year. This year the pick is Pennsylvania State Route 144, a little-known run through the north central part of the state. Members wait for that issue because it hands them somewhere new t

$HGTYMed

Bike broker Bennetts changes hands again as Hagerty swoops

Hagerty, a NYSE-listed collector vehicle insurer, will buy motorbike broker Bennetts from Lucida Group for £34m, with closing expected in Q3. The acquisition will fold Bennetts into Hagerty UK and is expected to triple Hagerty’s UK revenue to about £25m. Bennetts was acquired by Lucida in 2021 after Ardonagh bought it in 2020.

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.